Trial | NCT03380975  Report issue

Official Title

Role of Montelukast in Asthma and Allergic Rhinitis Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    600
To determine the effect of Montelukast in Asthma and Allergic rhinits patients
Montelukast is a potent and selective blocker of the CysLT1 receptor. Accordingly, a recent study has shown that Montelukast can improve symptoms of seasonal allergic rhinitis and asthma in patients with both diseases. For treatment of asthma, Montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form. Asthma and allergic rhinitis have been linked clinically for many years as "one airway one diseases". Patients with allergic asthma and rhinitis are significantly more likely to experience asthma attacks compared to patients with asthma alone. Side effects most commonly reported above placebo included headache, otitis media, upper respiratory infection, and pharyngitis
Study Started
Aug 28
2018
Primary Completion
Mar 25
2019
Study Completion
Jun 30
2019
Last Update
Jan 03
2020

Drug Montelukast 10mg

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening

  • Other names: Aireez

Montelukast 10 mg Experimental

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.

Criteria 

Inclusion Criteria:

Age >18 years
Signed Informed Consent
Clinical diagnosis of Asthma and Allergic Rhinitis

Exclusion Criteria:

Previous adverse reaction to Montelukast
History of hyper-eosinophilic disorder other than atopic disease
Female subjects who are pregnant, breast-feeding
Any significant and active pulmonary pathology other than asthma
No Results Posted